Retatrutide
Human trialsResearch education only. This profile does not establish benefits or safety for personal use.
At a glance
A GIP, GLP-1, and glucagon receptor agonist evaluated in the linked phase 2 obesity trial.
How it is studied
Combines activity at three hormone receptors. The linked 2023 trial provides human evidence, not a personal-use protocol.
Evidence & studies 2 curated
Read the population, methods, and limitations alongside each outcome. This selection is a starting point, not a systematic review.
Human randomized trial · 2023Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Read summary & limitations Human randomized trial · 2022LY3437943, a triple receptor agonist: a phase 1b trial in people with type 2 diabetes
Read summary & limitationsRisks & limits
- Clinical benefit and long-term safety are not established by the evidence curated here.
- Identity, purity, formulation, and route affect risk; a research label is not evidence of suitability for human use.
No universal storage, reconstitution, or administration protocol is provided. Product-specific instructions and evidence must be established separately.
Explore the half-life model
Half-life, visualized.
Each half-life halves the starting quantity.
Illustrative model, not a dosing schedule.
Model details & study source
A 2022 phase 1b Retatrutide study reported an approximate six-day half-life. This is a normalized, single-elimination teaching model, not measured blood levels, a clearance guarantee, an efficacy curve or a dosing schedule. Absorption and individual pharmacokinetics are not modeled. Read the original study